10:59 AM EDT, 07/23/2024 (MT Newswires) -- SeaStar Medical Holding ( ICU ) said Tuesday that it treated the first patient in a commercial setting with Quelimmune, a therapy to treat acute kidney injury, or AKI, in pediatric patients weighing 10 kilograms or up with sepsis or a septic condition requiring kidney replacement therapy.

AKI is characterized by a sudden and temporary loss of kidney function and can be a result of a variety of conditions such as COVID-19, sepsis, severe trauma, and surgery.

The company said that with this move, it has met the Aug. 20 deadline given by the US Food and Drug Administration to start patient treatments.

Shares of SeaStar Medical Holding ( ICU ) rose past 8% in recent trading activity.

Price: 7.42, Change: +0.57, Percent Change: +8.35